ABBV ▼ -0.1% - AbbVie Inc. $ABBV - AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting AbbVie shares moved down 0.1% today as the company announced upcoming presentations of Phase 3 data for etentamig and its broader multiple myeloma pipeline at the 2026 International Myeloma Society Meeting. The modest decline suggests investors viewed the announcement as routine disclosure of previously expected clinical presentations rather than a catalyst for immediate movement. 17-SEP-2026 08:30 AM ET